SCHEMBL3164337

SCHEMBL3164337

CCCOc1cccc(C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)B(O)O)[C@@H](C)O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 6/20 0.51
ELANE P08246 1/20 0.51
CTSG P08311 1/20 0.51
CYP3A4 P08684 1/20 0.51
PSMB1 P20618 1/20 0.51
CMA1 P23946 1/20 0.51
PSMB8 P28062 1/20 0.51
PSMB9 P28065 1/20 0.51
PSMB10 P40306 1/20 0.51
PSMB2 P49721 1/20 0.51
KMT2A Q03164 2/20 0.46
NR1H4 Q96RI1 1/20 0.46
ADRB2 P07550 1/20 0.45
ADRB1 P08588 1/20 0.45
ADRB3 P13945 1/20 0.45
SMPD1 P17405 3/20 0.44
ALDH1A1 P00352 2/20 0.44
KAT6A Q92794 1/20 0.44
MEN1 O00255 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244976 0.88 TAS1R3 (0.57) PSMB5ELANECTSGCYP3A4PSMB1
SCHEMBL606374 0.82 KMT2A (0.48) KMT2ANR1H4ADRB2ADRB1ADRB3
SCHEMBL606373 0.82 KMT2A (0.48) KMT2ANR1H4ADRB2ADRB1ADRB3
SCHEMBL3175000 0.80 PSMB5 (0.66) PSMB5ELANECTSGCYP3A4PSMB1
SCHEMBL3170541 0.79 PSMB5 (0.59) PSMB5ELANECTSGCYP3A4PSMB1
SCHEMBL3159944 0.78 PSMB5 (0.58) PSMB5ELANECTSGCYP3A4PSMB1
SCHEMBL13702136 0.78 KMT2A (0.66) KMT2ANR1H4ADRB2ADRB1ADRB3
SCHEMBL3174593 0.75 PSMB5 (0.57) PSMB5ELANECTSGCYP3A4PSMB1
SCHEMBL10243732 0.75 PSMB5 (0.52) PSMB5ELANECTSGCYP3A4PSMB1
SCHEMBL2928226 0.75 PSMB5 (0.58) PSMB5ELANECTSGCYP3A4PSMB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 US disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 US disclosed
US-8058262-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-11-15 US disclosed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PSMB5 2/4885ELANE 1707/4885CTSG 781/4885
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885ELANE 1707/4885CTSG 781/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885ELANE 1707/4885CTSG 781/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885ELANE 1707/4885CTSG 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.